Share the post "Shareholding Pattern: Shareholding Pattern Vista Pharmaceuticals Ltd. An Examination of Financial Performance for FY (Q4-Mar 2023-2024)"
Vista Pharmaceuticals Ltd. has unveiled its latest shareholding reports, covering the quarter and the first half of the fiscal year ending on (Q4-Mar 2023-2024).This comprehensive report offers a deep dive into the company’s shareholding landscape, including details on Promoters, promoter groups, Foreign investors, public investors, and government entities. Through meticulous comparative analysis, it tracks the evolution of shareholding percentages and quantities, highlighting any shifts in ownership dynamics. Investors gain invaluable insights into the company’s ownership structure and the evolving investment landscape.
Shareholder Name |
Previous Quater Quantity(In Crores) |
Current Quater Quantity(In Crores) |
Previous Quater Shares(in %) |
Current Quater Shares(in %) |
Quater to Quater Difference |
Promoters |
1.30 |
1.30 |
27.81 |
35.44 |
+7.63 % |
Public |
3.39 |
2.38 |
72.16 |
64.52 |
-7.64 % |
DII
|
0.00 |
0.00 |
0.03 |
0.04 |
+0.01 % |
FII
|
0 |
0 |
0 |
0 |
0 |
Government
|
0.00 |
0.00 |
0 |
0 |
0 |
Promoters’ shareholding increased from 27.81% in December 2023 to 35.44% in March 2024. This rise indicates that the promoters have strengthened their control over Company during this period.The percentage of shares held by the public decreased from 72.16% in December 2023 to 64.52% in March 2024.This reduction indicates that the public’s stake in the company diminished during this period.DIIs (Domestic Institutional Investors) shareholding increased from 0.03% in December 2023 to 0.04% in March 2024 , indicating that domestic institutions increased their stake in the company by 0.01% . During quater from December 2023 to March 2024, Goverenment ownership remained steady at 0%.This indicates that the government’s stake in the company remained consistent during this period.
Let’s delve deeper into the statistics of the investors, which could have contributed to the fluctuations in the shareholding pattern.
Shareholder Name |
Previous Quarter Quantity (In crores) |
Current Quarter Quantity (In crores) |
Previous Quarter Shares (in %) |
Current Quarter Shares (in %) |
Quarter-to-Quarter Difference (%) |
ANDHRA PRADESH INDUSTRIAL DEVELOPMENT CORPORATION LIMITED |
0.075 |
0.075 |
1.6 |
2.04 |
+ 0.44 % |
VISTA PHARMACEUTICALS INC |
0.658 |
0.658 |
14.03 |
17.88 |
+ 3.85 % |
DHANANJAYA ALLI |
0.289 |
0.289 |
6.16 |
7.85 |
+ 1.69 % |
VASANT V ALLI |
0.160 |
0.160 |
3.41 |
4.35 |
+ 0.94 % |
VAMSI V ALLI |
0.042 |
0.042 |
0.89 |
1.13 |
+ 0.24 % |
ROSHNI ALLI |
0.034 |
0.034 |
0.73 |
0.93 |
+ 0.2 % |
PADMAVATHI ALLI |
0.046 |
0.046 |
0.99 |
1.26 |
+ 0.27 % |
ANDHRA PRADESH INDUSTRIAL DEVELOPMENT CORPORATION LIMITED has showcased a remarkable improvement in profitability for this quarter, registering a significant increase of 0.44 % in net profit. This signifies adept cost management strategies, amplified revenue streams, or a harmonious blend of both, underscoring the shareholder’s positive impact on the company’s financial health.VISTA PHARMACEUTICALS INC has showcased a remarkable improvement in profitability for this quarter, registering a significant increase of 3.85 % in net profit. This signifies adept cost management strategies, amplified revenue streams, or a harmonious blend of both, underscoring the shareholder’s positive impact on the company’s financial health.DHANANJAYA ALLI has showcased a remarkable improvement in profitability for this quarter, registering a significant increase of 1.69 % in net profit. This signifies adept cost management strategies, amplified revenue streams, or a harmonious blend of both, underscoring the shareholder’s positive impact on the company’s financial health.VASANT V ALLI has showcased a remarkable improvement in profitability for this quarter, registering a significant increase of 0.94 % in net profit. This signifies adept cost management strategies, amplified revenue streams, or a harmonious blend of both, underscoring the shareholder’s positive impact on the company’s financial health.VAMSI V ALLI has showcased a remarkable improvement in profitability for this quarter, registering a significant increase of 0.24 % in net profit. This signifies adept cost management strategies, amplified revenue streams, or a harmonious blend of both, underscoring the shareholder’s positive impact on the company’s financial health.ROSHNI ALLI has showcased a remarkable improvement in profitability for this quarter, registering a significant increase of 0.2 % in net profit. This signifies adept cost management strategies, amplified revenue streams, or a harmonious blend of both, underscoring the shareholder’s positive impact on the company’s financial health.PADMAVATHI ALLI has showcased a remarkable improvement in profitability for this quarter, registering a significant increase of 0.27 % in net profit. This signifies adept cost management strategies, amplified revenue streams, or a harmonious blend of both, underscoring the shareholder’s positive impact on the company’s financial health.
Shareholder Name |
Previous Quarter Quantity (In Crores) |
Current Quarter Quantity (In Crores) |
Previous Quater Shares (in %) |
Current Quater Shares (in %) |
Quater-to-Quater Difference (%) |
Directors and their relatives (excluding independent directors and nominee directors) |
1.391 |
0.500 |
29.65 |
13.59 |
-16.06 % |
UMAKANTH KATTA |
0.540 |
0.500 |
11.51 |
13.59 |
+ 2.08 % |
Resident Individuals holding nominal share capital up to Rs. 2 lakhs |
0.932 |
0.952 |
19.88 |
25.89 |
+ 6.01 % |
Resident Individuals holding nominal share capital in excess of Rs. 2 lakhs |
0.729 |
0.588 |
15.55 |
15.99 |
+ 0.44 % |
KAMAL GADALAY |
0.179 |
0.180 |
3.82 |
4.9 |
+ 1.08 % |
SURESH GADALAY |
0.284 |
0.286 |
6.06 |
7.76 |
+ 1.7 % |
Non Resident Indians (NRIs) |
0.312 |
0.312 |
6.64 |
8.48 |
+ 1.84 % |
KESHAVA MURTHY SHIVA SHANKAR |
0.126 |
0.126 |
2.68 |
3.41 |
+ 0.73 % |
RAJENDAR BALAKRISHNA |
0.070 |
0.070 |
1.49 |
1.9 |
+ 0.41 % |
Bodies Corporate |
0.021 |
0.021 |
0.44 |
0.56 |
+ 0.12 % |
Any Other (specify) |
0.000 |
0.000 |
0 |
0.01 |
+ 0.01 % |
Pavan sathvik Gilaka |
0.452 |
0 |
9.64 |
0 |
-9.64% |
Murali Meraga |
0.398 |
0 |
8.49 |
0 |
-8.49% |
Deepthi Pachipala |
0.120 |
0 |
2.56 |
0 |
-2.56% |
Observations indicate a sizeable -16.06 % variance in Directors and their relatives (excluding independent directors and nominee directors)’s fiscal performance between quarters, necessitating thorough investigation of salient aspects to enable future-proof strategies centered around lasting development.Spearheading a savvy charge towards increased profitability, UMAKANTH KATTA lifts the bar with a remarkable 2.08 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, Resident Individuals holding nominal share capital up to Rs. 2 lakhs lifts the bar with a remarkable 6.01 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, Resident Individuals holding nominal share capital in excess of Rs. 2 lakhs lifts the bar with a remarkable 0.44 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, KAMAL GADALAY lifts the bar with a remarkable 1.08 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, SURESH GADALAY lifts the bar with a remarkable 1.7 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, Non Resident Indians (NRIs) lifts the bar with a remarkable 1.84 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, KESHAVA MURTHY SHIVA SHANKAR lifts the bar with a remarkable 0.73 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, RAJENDAR BALAKRISHNA lifts the bar with a remarkable 0.41 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, Bodies Corporate lifts the bar with a remarkable 0.12 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Spearheading a savvy charge towards increased profitability, Any Other (specify) lifts the bar with a remarkable 0.01 % enhancement in net profit, revealing adroit resource allocation and sharpened commercial instincts.Pavan sathvik Gilaka had 9.64% of shares in the previous quarter but exited in the current quarter.Murali Meraga had 8.49% of shares in the previous quarter but exited in the current quarter.Deepthi Pachipala had 2.56% of shares in the previous quarter but exited in the current quarter.
Shareholder Name |
Previous Quarter Quantity (In Crores) |
Current Quarter Quantity (In Crores) |
Previous Quater Shares (in %) |
Current Quater Shares (in %) |
Quater-to-Quater Difference (%) |
Mutual Funds/ |
0.001 |
0.001 |
0.03 |
0.04 |
+ 0.01 % |
The latest quarter saw a considerable enhancement in profitability for Mutual Funds/, reflecting an uptick of 0.01 % in their net earnings. Such an outcome implies the successful implementation of sound cost optimization techniques and increased income sources, ultimately highlighting the favorable effect of the investor on the corporation’s overall monetary welfare.
[my_shortcode1 values=”Vista Pharmaceuticals Ltd. “]